WISQOL (Wisconsin Stone Quality of Life questionnaire) is a disease specific, health related quality of life measure designed for patients who form kidney stones. The purpose of this study was to demonstrate the external and convergent validity of WISQOL and assess its psychometric properties. At the WISQOL creation site (development sample) and at 8 geographically diverse centers in the United States and Canada (consortium sample) patients with a history of kidney stones were recruited. Item response option variability, correlation patterns and internal consistency were compared between samples. Convergent validity was assessed by patients who completed both WISQOL and SF-36v2® (36-Item Short Form Health Survey, version 2). Results were analyzed in 1,609 patients, including 275 in the development sample and 1,334 in the consortium sample. Response option variability patterns of all items were acceptable. Internal WISQOL consistency was acceptable. Intersample score comparisons revealed few differences. For both samples the domain-total WISQOL score correlations exceeded 0.86. Item level analyses demonstrated suitable variation, allowing for discriminatory scoring. At the time that they completed WISQOL, patients with stones and stone related symptoms scored lowest for health related quality of life. Patients with stones but no symptoms and those with no stones scored higher. The convergent validity substudy confirmed the ability of WISQOL to identify stone specific decrements in health related quality of life that were not identified on SF-36v2. WISQOL is internally consistent and discriminates among patients with different stone statuses and symptoms. WISQOL is externally valid across the North American population. It may be used for multicenter health related quality of life studies in kidney stone disease.

More than 850 million individuals worldwide, accounting for 10–15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota — a dynamic ecosystem that both influences host health and is itself influenced by changes in the host. Available evidence supports the existence of functional connections between resident microorganisms and kidney health that are altered in the context of specific kidney diseases, including acute kidney injury, chronic kidney disease and renal stone disease. Moreover, promising data from preclinical studies suggest that targeting of gut microbial pathways may provide new therapeutic opportunities for the treatment of kidney disease. This Roadmap describes current understanding of the mechanisms by which microorganisms regulate host organ function, the effects of kidney disease on the gut microbiome, and how these insights may contribute to the development of microbe-targeted therapeutics. We highlight key knowledge gaps that remain to be addressed and strategies for addressing these, outlining both the promise and the potential pitfalls of leveraging our understanding of the gut microbiota to better understand and treat kidney disease.

INTRODUCTION: Kidney stone patients have lower health-related quality of life (HRQOL) than non-stone formers. Among active stone patients (those with stones), those with symptoms have lower HRQOL than those without. But little is known about whether asymptomatic stones affect patients’ HRQOL. METHODS: A sample of asymptomatic stone formers was assembled by identifying patients who reported no symptoms on the disease-specific Wisconsin Stone Quality of Life (WiSQoL) questionnaire (n=351). Of these, 107 were identified (M:F 61:46; 53±17 y; BMI 29.5±7.6). Patients were mostly recurrent (78%), and 42% thought they had stones at the time of the WiSQoL. Patients’ WisQoL responses were compared by self-reported stone status (yes/no), actual stone status (yes/no, corroborated from imaging and medical records), age, gender, and duration of stones. RESULTS: Of patients reporting stones at the time of the questionnaire (42% of sample), 37 (82%) were correct about it. Of patients who reported not having stones (49% of sample), 29 (55%) were correct. WiSQoL results were lower (worse HRQOL) among patients with stones vs. those without, regardless of whether they knew their actual stone status. CONCLUSIONS: Asymptomatic patients with current stones, whether they are aware of them or not, may have lower HRQOL. These results suggest that (a.) some patients may not be fully aware of their stone-related symptoms or are better able to handle them than others, and (b.) because of the potential impact on HRQOL, some patients may benefit from definitive knowledge of their stone status as this may inform decision-making for subsequent stone management.

Introduction: Cystinuria is a rare cause of urolithiasis. Affected patients have an earlier onset and more aggressive disease than patients with other stone etiologies. We assessed the health-related quality of life (HRQOL) of cystine stone-forming patients using the disease-specific Wisconsin Stone Quality of Life questionnaire (WISQOL). Methods: Cystine patients treated in our stone clinics (n = 12) completed the WISQOL; information about medical and stone histories was gathered. Patients were matched with noncystine stone formers (n = 12) for gender, age, and comorbidities. In addition, a second control group (n = 90), also from our institution and consisting of mixed calcium stone formers, was included. WISQOL responses were compared between groups. Results: Cystine patients had significantly lower total WISQOL scores than noncystine patients. Compared with noncystine stone formers, cystine stone formers also had lower HRQOL scores for subscales (domains) related to social impact, emotional impact, disease impact, and vitality (p ≤ 0.04 for all). On specific items, cystine patients reported significantly more sleep problems (p = 0.02), more bother with nocturia (p = 0.03), and feeling tired or fatigued (p = 0.02). Among those with current stones, cystine patients scored lower than noncystine patients for total score and in two of four domains. Conclusions: Using a stone-specific questionnaire, patients with cystine stones have lower HRQOL compared with noncystine stone formers. Identifying and addressing specific areas of decrement in patients with cystine stones may improve disease management and patients' HRQOL.